Virtual Library
Start Your Search
P. Venclíčková
Author of
-
+
P3.02b - Poster Session with Presenters Present (ID 494)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P3.02b-030 - Single Institution Experience with EGFR Gene Mutation Analysis and Treatment of EGFR Positive Patients in the Years 2010 to 2015 (ID 5022)
14:30 - 14:30 | Author(s): P. Venclíčková
- Abstract
Background:
Our department is among several centers in the Czech Republic which comprehensively diagnose and treat patients with lung cancer, including mutational analysis of EGFR and subsequent personalised treatment.
Methods:
We present the results of mutational analysis of EGFR gene, and effects of treatment in patients with NSCLC with mutations in this gene who were in treatment in our department in the years 2010 to 2015. We processed the data to get a five year long, single institution experience.
Results:
In 786 examined patients, 65% were male. Average age of was 65.1 years, median 66 years. In these 786 patients, 1039 analyses of EGFR mutation status were done. 10% (79 patients) were EGFR positive. Within the group of EGFR-positive patients 65% were female. Average age was 65.6 years, median age 66 years. 62% (46 patients) with positive EGFR mutation were non-smokers, 33% (25 patients) former smokers and 5% (4 patients) smokers. 92% of patients had adenocarcinomas. The most frequent mutations were in exon 19 and 21. 65 % (51 patients) of the EGFR positive group were treated with TKI, in some of the lines of treatment. TKI was mostly used in the first line of treatment. 35% (28 EGFR positive patients) were not treated with TKI because of PS 3 or 4 (11 patients), prior radical surgery (9 patients) or radical radiotherapy (1 patient). 7 patients left for other center. Median PFS in the group of 23 patients, who were treated with TKI in first line, was 8.0 months (average PFS 8.9 months). The average OS of 31 patients who were treated in the years 2010 to 2015, including lines with chemotherapy, was 18.3 months (median 17, the longest survival 56 and the shortest 2 months). At the beginning of April 2016, 20 patients were still in treatment. The longest survival in this group was 61 months. Three patients with mutation T790M, occurring simultaneously with deletion in exon 19 showed surprisingly good results. One patient was still alive at the beginning of April 2016, and OS of the remaining two patients was 43 and 56 months.
Conclusion:
The majority of EGFR positive patients were treated with TKI, mostly in the first line. The rest of the patients either did not need TKI therapy, or TKI was not indicated because of their overall poor condition. Our experience is similar to the results of larger multicenter studies.
